Literature DB >> 3573825

Determination of silica-purified plasma calcitonin for the detection and management of medullary thyroid carcinoma: comparison of two provocative tests.

H Gharib, P C Kao, H Heath.   

Abstract

Radioimmunoassays for human calcitonin in whole plasma are limited in sensitivity and specificity; basal values of calcitonin are often undetectable in normal plasma, and nonspecific increases are occasionally found in seemingly healthy persons. We avoided these problems by applying a silica-cartridge extraction-concentration technique for calcitonin assay, and the effectiveness of two calcitonin stimulation tests in healthy volunteers and patients with medullary thyroid carcinoma was compared. The radioimmunoassay was improved by using a new antiserum and a sequential incubation procedure that reduced the previously used sample-volume requirement and incubation period substantially. This method was used to measure mean basal plasma levels of calcitonin (+/-SD) in 45 normal men (8.2 +/- 5 pg/ml) and 47 normal women (4.8 +/- 4 pg/ml) (P less than 0.001). Calcium infusions (2 mg/kg over 5 minutes) in 18 normal men and 37 normal women yielded a significantly greater secretory response than did pentagastrin (0.5 micrograms/kg as a bolus). Among 12 patients with medullary thyroid carcinoma, pentagastrin seemed to be a better secretagogue than calcium (P less than 0.001). We recommend routine measurement of plasma silica-extractable calcitonin and pentagastrin injection as the provocative test of choice for the detection and management of medullary thyroid carcinoma. The short calcium-infusion test is a good alternative.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3573825     DOI: 10.1016/s0025-6196(12)65441-x

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  7 in total

Review 1.  Determination of calcitonin levels in C-cell disease: clinical interest and potential pitfalls.

Authors:  Giuseppe Costante; Cosimo Durante; Zélia Francis; Martin Schlumberger; Sebastiano Filetti
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2009-01

Review 2.  Calcitonin as a biomarker of C cell disease: recent achievements and current challenges.

Authors:  Giuseppe Costante; Domenico Meringolo
Journal:  Endocrine       Date:  2020-01-10       Impact factor: 3.633

3.  Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma.

Authors:  J A van Heerden; C S Grant; H Gharib; I D Hay; D M Ilstrup
Journal:  Ann Surg       Date:  1990-10       Impact factor: 12.969

4.  The calcitonin levels can sometimes mislead parathyroid surgeons in patients with chronic kidney disease and renal hyperparathyroidism: report of a case.

Authors:  Ralph Schneider; Johanna E Schaumburg; Detlef K Bartsch; Katja Schlosser
Journal:  Surg Today       Date:  2013-04       Impact factor: 2.549

5.  Stimulated calcitonin cut-offs by different tests.

Authors:  Laura Fugazzola
Journal:  Eur Thyroid J       Date:  2013-01-16

6.  Calcitonin levels in normal individuals with new highly sensitive chemiluminescent enzyme immunoassay.

Authors:  H Suzuki
Journal:  J Clin Lab Anal       Date:  1998       Impact factor: 2.352

7.  An introduction to managing medullary thyroid cancer.

Authors:  Jan Willem de Groot; Thera P Links; Robert Mw Hofstra; John Tm Plukker
Journal:  Hered Cancer Clin Pract       Date:  2006-07-15       Impact factor: 2.857

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.